Defining the clinical course of multiple sclerosis: the 2013 revisions.

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

[1]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[2]  M. Battaglini,et al.  Cortical lesions in radiologically isolated syndrome , 2011, Neurology.

[3]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[4]  D. Goodin,et al.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.

[5]  J. Stockman.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2011 .

[6]  L. Kappos,et al.  Measuring disability in relapsing-remitting MS , 2010, Neurology.

[7]  P. Calabresi,et al.  Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for Neurodegeneration , 2010, Neurotherapeutics.

[8]  F. Barkhof,et al.  Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis , 2010, Neuroradiology.

[9]  P. Rieckmann,et al.  The natural history of primary progressive multiple sclerosis , 2009, Neurology.

[10]  F. Moore.  INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.

[11]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[12]  O. Kantarci,et al.  Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease , 2009, Multiple sclerosis.

[13]  Lucien Rumbach,et al.  Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. , 2009, Archives of neurology.

[14]  F. Barkhof,et al.  Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. , 2009, Neuroimaging clinics of North America.

[15]  Jeffrey A. Cohen,et al.  Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.

[16]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[17]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[18]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[19]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[20]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[21]  Edmus Coordinating.  Natural history of multiple sclerosis: A unifying concept , 2006 .

[22]  G. Cutter,et al.  MRI as a marker for disease heterogeneity in multiple sclerosis , 2005, Neurology.

[23]  A J Thompson,et al.  Is inflammation important in early PPMS? a longitudinal MRI study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[25]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[26]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[27]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[28]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[29]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[30]  W. I. McDonald,et al.  Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis , 1996, Neurology.

[31]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.

[32]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[33]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.